Want to see TSE:CSCI full AI Analyst Report?
CSCI Stock Chart & Stats
C$7.50
-C$0.05(-0.65%)
At close: 4:00 PM EDT
C$7.50
-C$0.05(-0.65%)
Day’s Range― - ―
52-Week RangeC$3.30 - C$14.80
Previous CloseN/A
Volume1.00
Average Volume (3M)607.00
Market Cap
C$8.57M
Enterprise ValueC$1.56M
Total Cash (Recent Filing)C$5.27M
Total Debt (Recent Filing)C$1.95M
Price to Earnings (P/E)―
Beta2.68
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.03
Shares Outstanding996,394
10 Day Avg. Volume528
30 Day Avg. Volume607
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.29
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Gross Margin And LossesGross-margin expansion from roughly 35% to 45%, alongside a materially smaller TTM loss, indicates operating economics are improving. If sustained, this progress can strengthen the earnings base and reduce the scale of funding needed to support the business.
Conservative Capital StructureDebt of about $2.0M against $14.8M of equity produces a roughly 0.13 debt-to-equity ratio, an improved and relatively conservative capital structure. This provides greater financial flexibility and lowers balance-sheet pressure while the company develops its therapeutic products.
Revenue StabilizationThe return to modest TTM revenue growth suggests the top line has begun to stabilize after the prior-year decline. Continued stabilization would provide a more reliable base for gross-margin improvement, operating leverage, and future commercialization efforts.
Bears Say
Persistent UnprofitabilityCOSCIENS remains deeply unprofitable despite narrowing losses, with a negative net margin and sharply negative return on equity. Until revenue scale or operating efficiency improves substantially, the company is unlikely to generate dependable earnings or shareholder returns.
Ongoing Cash BurnNegative operating and free cash flow show that the business continues to consume cash rather than fund itself internally. Although operating outflows improved versus earlier periods, persistent cash burn can constrain investment capacity and increase reliance on future financing.
Limited Top-Line GrowthRevenue growth remains modest and follows a prior-year decline, indicating that commercial traction is not yet strong or consistently established. This limited scale makes it harder to absorb operating costs, convert margin gains into profit, and support sustained cash generation.
COSCIENS Biopharma News
CSCI FAQ
What was COSCIENS Biopharma’s price range in the past 12 months?
COSCIENS Biopharma lowest stock price was C$3.30 and its highest was C$14.80 in the past 12 months.
What is COSCIENS Biopharma’s market cap?
COSCIENS Biopharma’s market cap is C$8.57M.
When is COSCIENS Biopharma’s upcoming earnings report date?
COSCIENS Biopharma’s upcoming earnings report date is Nov 17, 2026 which is in 24 days.
How were COSCIENS Biopharma’s earnings last quarter?
COSCIENS Biopharma released its earnings results on Aug 11, 2026. The company reported -C$0.267 earnings per share for the quarter.
Is COSCIENS Biopharma overvalued?
According to Wall Street analysts COSCIENS Biopharma’s price is currently Overvalued.
Does COSCIENS Biopharma pay dividends?
COSCIENS Biopharma does not currently pay dividends.
What is COSCIENS Biopharma’s EPS estimate?
COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSCIENS Biopharma have?
COSCIENS Biopharma has 996,394 shares outstanding.
What happened to COSCIENS Biopharma’s price movement after its last earnings report?
COSCIENS Biopharma reported an EPS of -C$0.267 in its last earnings report. Following the earnings report the stock price went up 3.15%.
Which hedge fund is a major shareholder of COSCIENS Biopharma?
Currently, no hedge funds are holding shares in TSE:CSCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Technical Analysis
BetterLife Pharma
―
PharmaTher Holdings Ltd
―
Glow LifeTech
―
Marvel Biosciences Corp
―
PharmAla Biotech Holdings, Inc.
―